Dr Helen Bright is an esteemed virologist and immunologist with more than 30 years of experience in infectious diseases within the biopharmaceutical industry. In her role as CSO at Centauri Therapeutics, Helen has shaped the scientific strategy behind the company’s therapeutic pipeline, including clinical candidate CTX-187, as well as leading the research and development of the Alphamer® platform.
Throughout her career, Helen has held senior scientific and operational leadership positions at global pharmaceutical companies including AstraZeneca, Pfizer and GSK, where she supported the advancement of novel small molecule, antibody and vaccine candidates from discovery to the clinic and through to commercial launch. Helen was also previously Head of Infection Biology at the Medicines Discovery Catapult, where she was supported UK academic and SME innovators in the discovery and development of novel anti-infectives, vaccines and diagnostics.
Helen holds a PhD in Virology and Immunology from Newcastle upon Tyne University.